Immunic to Participate in Investor Conferences in March

NEW YORK, March 3, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March:

• March 8-11: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jason Tardio, President and Chief Operating Officer of Immunic, will participate in a fireside chat on Wednesday, March 11, at 10:40 am ET at this conference in Miami. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.

Dr. Vitt, Mr. Tardio and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Leerink representative or Jessica Breu at: jessica.breu@imux.com.

• March 17-18: Stifel 2026 Virtual CNS Forum. Dr. Vitt and Mr. Tardio will participate in a fireside chat on Wednesday, March 18, at 4:00 pm ET at this virtual conference. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.

Dr. Vitt, Mr. Tardio and Mrs. Breu will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Stifel representative or Jessica Breu at: jessica.breu@imux.com.
 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases such as celiac disease, inflammatory bowel disease, and Graft-versus-Host-Disease. IMU-381 comprises next-generation molecules in preclinical testing for neurologic, gastrointestinal and other autoimmune diseases leveraging the company’s Nurr1 platform. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
 

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

Secarna Pharmaceuticals and Curie.Bio Expand Existing Partnership

• Expansion of existing scientific and strategic collaboration agreement announced in May 2025
• Secarna to support Curie.Bio in identifying oligonucleotide candidates for its company ventures

Martinsried (Munich), Germany, March 3, 2026 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the expansion of the existing scientific and strategic collaboration agreement with Curie.Bio announced in May 2025. The expansion includes Secarna’s support in identifying oligonucleotide candidates using its proprietary OligoCreator^® platform for research and development projects conducted by Curie.Bio portfolio companies.

“The decision to expand our cooperation serves as validation of our fruitful partnership with Curie.Bio so far,” said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals. “It shows a high level of trust between our teams who excellently work together to discover and develop new therapies against difficult to treat diseases. Our shared vision of transforming scientific innovation into life-changing therapies guides our daily work, driving us to efficiently generate measurable results in discovering and developing best-in-class drug products.”

Secarna’s AI-empowered OligoCreator^® platform seamlessly integrates diverse delivery technologies as well as proprietary safety and efficacy testing systems to identify and characterize oligonucleotide therapeutics with exceptional speed, safety, and efficacy – strengthening its position as a pivotal tool in transforming previously untreatable conditions into treatable ones and profoundly shaping the future of medicine.

About Secarna Pharmaceuticals

Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics, offering hope to patients facing conditions that are beyond the reach of current approaches and modalities. With the Company’s proprietary AI-empowered OligoCreator^® platform, which includes multiple delivery technologies, Secarna identifies and characterizes oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By delivering these novel therapeutics to the cells, organs, or tissues where they are needed, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Secarna’s unique OligoCreator^® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine. www.secarna.com

About Curie.Bio

Curie.Bio is a $1.25B global venture capital firm that helps founders discover and develop important new medicines. The firm partners with founders by investing in existing companies, creating focused spinouts, and building companies from scratch. Curie.Bio’s model uniquely combines capital with hands-on drug development, operating as both a drug discovery copilot and an investor. Its 100+ person team of experienced drug hunters, drug makers, and operators works closely with founders on a day-to-day basis to improve decision-making and increase the probability of success. Curie.Bio helps founders avoid critical early mistakes and ensures they have the right scientific plan, data package, and narrative to maximize long-term value creation. Curie.Bio invests across the lifecycle of therapeutic development, from preclinical discovery through clinical proof-of-concept. Learn more at www.curie.bio

Contact

Secarna Pharmaceuticals GmbH & Co. KG
Konstantin Petropoulos, PhD, MBA
CEO
Phone: +49 (0)89 215 46 375

Email: info@secarna.com

 
Secarna Pharmaceuticals

For media inquiries
MC Services AG

Anne Hennecke/Lydia Robinson-Garcia
Phone: +49 (0)211 52 92 52 15

Email: secarna@mc-services.eu

NVision Establishes First Strategic European Hub at University of Cambridge to Advance Clinical Translation of Quantum-Enhanced Metabolic MRI

The installation of the POLARIS™ platform at the Department of Radiology at the University of Cambridge supports research in oncology, neurodegeneration, and cardiovascular disease.

ULM, Germany & CAMBRIDGE, United Kingdom — March 3, 2026 — NVision, a quantum healthcare company, today announced the establishment of its first long-term research partnership in Europe at the Department of Radiology, University of Cambridge. This deployment creates a European research center for POLARIS, NVision’s proprietary system that produces the metabolic imaging agent for standard MRI.

This partnership follows a year of international expansion. In 2025, NVision collaborated with leading institutions, including Memorial Sloan Kettering Cancer Center, to demonstrate the feasibility of standardized, high-throughput metabolic imaging. Building on this momentum, NVision and researchers at Cambridge University’s Department of Radiology are now establishing a translational research pipeline with POLARIS, creating a direct route for quantum-enhanced diagnostics to move from the lab to the clinic.

“In 2025, we demonstrated that quantum in healthcare is a deployed reality. In 2026, we are integrating POLARIS into leading translational research environments,” said Sella Brosh, CEO of NVision. “Together with our partners at Cambridge, we have two objectives: to develop clinical applications for quantum-enhanced metabolic MRI that have the potential to radically improve patient outcomes, and to establish robust metabolic biomarkers that accelerate decision-making in drug development.”

POLARIS boosts the MRI signal of sugars over 10,000x through a process known as hyperpolarization, making it possible for standard MRI systems to “light up” and measure cell metabolism in real-time. It is the first commercially available quantum-based polarizer, using parahydrogen-induced polarization (PHIP) to produce metabolic imaging agent in under three minutes. By visualizing disease activity in real-time, POLARIS empowers researchers to assess therapy effectiveness within days rather than months.

The Cambridge team will leverage the POLARIS platform to conduct research across cancer, neurodegeneration, and cardiovascular diseases, with an initial focus on:

• Liver Cancer: Despite being the third leading cause of cancer deaths globally, liver tumors remain difficult to characterize in cirrhotic tissue using standard imaging. The team aims to use POLARIS to reveal early metabolic changes in the liver before tumors form.
• Multiple Sclerosis (MS): While standard MRI captures blood–brain barrier leakage and lesion burden, it offers limited insight into lesion biology or ongoing tissue injury. POLARIS provides a direct functional readout of tissue metabolism, offering deeper insights to better guide treatment for the 3 million people living with MS worldwide.

Leading this initiative at the University of Cambridge are Ferdia Gallagher, Head of the Department of Radiology, and Joshua Kaggie, Director of the Preclinical Imaging Facility. Their team will use POLARIS to uncover the drivers of these conditions and inform the development and validation of new drugs.

“Our team is excited to be able to use POLARIS to probe the metabolism of diseases, particularly in cancer and within the brain,” said Professor Ferdia Gallagher. “Our aim is to detect early changes in metabolism as a predictor of tumor formation, as well as differentiating more aggressive from less aggressive disease based on specific metabolic fingerprints. We also want to explore how changes in metabolism with treatment can be used as a measure of early and successful response to treatment. Ultimately, we plan to translate these findings into the clinic to benefit patients in the future.”

NVision plans to deploy systems at leading global research centers throughout 2026, with the goal of beginning clinical studies next year.

About NVision Imaging

NVision Imaging was founded in 2015 and is headquartered in Ulm, Germany. By leveraging advances in quantum physics, NVision enables real-time visualization of metabolism on standard MRI, aiming to set a new standard for faster drug development, earlier diagnosis, and better therapy decisions. Learn more at nvision-imaging.com.

Contact:
Leah Wiedenmann
NVision Imaging Technologies
leah.wiedenmann@nvision-imaging.com
+49-176-247-33866

MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation

Geneva, Switzerland – March 3, 2026 – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today provided a post-listing corporate update and published its March 2026 investor presentation.

Alexandre Capet, Chief Executive Officer of MindMaze Therapeutics, stated, “Building on solid foundations, we are executing our roadmap to expand access to evidence-based neurotherapies and further deliver meaningful clinical benefits to patients across the continuum of care. Since completing our business combination and public listing, our priority has been disciplined execution, streamlining our portfolio and organization to concentrate on our priorities. In the United States, we are actively engaging with provider groups to broaden adoption of our platform. In Europe, we are advancing reimbursement-focused initiatives. In parallel, we are progressing pharmaceutical collaboration discussions. The operational momentum achieved to date positions us well to deliver continued meaningful progress throughout 2026.”

Commercial Expansion in the United States
Leveraging compelling real-world evidence and its unique reimbursement code for at-home utilization, MindMaze Therapeutics is advancing discussions with selected U.S.-wide provider groups and commercial partners to broaden the adoption of its platform. The Company is working toward the potential finalization of an agreement in the near term.

The Company has also initiated measures to strengthen its U.S.-based commercial organization, including recruitment efforts for field specialists and continued consolidation of medico-economic evidence supporting improved clinical outcomes and cost efficiency across neurological indications, notably through anticipated clinical readouts from ongoing studies conducted at Vibra Healthcare hospitals and Mount Sinai Hospital.

Advancing Market Access in Europe
MindMaze Therapeutics is advancing reimbursement-focused clinical initiatives in Europe, including the planned initiation, in the coming weeks, of SwissNeuroRehab and React-AVC studies. These initiatives are designed to further demonstrate the clinical and socio-economic benefits of the Company’s integrated neurotherapeutic platform compared to standard models of care and to support broader reimbursement and market access across European markets.

The Company’s solutions are already deployed across more than 100 hospitals and neurorehabilitation facilities in Europe, including leading academic centers.

Organizational Focus, Integration and Governance Update
Following the completion of its business combination, MindMaze Therapeutics has defined a structured integration plan to optimize its organization and portfolio. For selected non-core assets outside neurology, the Company is evaluating strategic alternatives, including potential outlicensing or disposal. The integration plan is designed to enhance capital efficiency, reinforce strategic focus and maximize shareholder value.

In this context, Gregory Van Beek and Michael Stünkel have stepped down from the Board of Directors. The Board thanks Mr. Van Beek and Mr. Stünkel for their contributions and support throughout the business combination and subsequent transition period. Proposals for the election of successor directors will be submitted at the next annual general meeting of shareholders.
 

The Company’s March 2026 investor presentation, which includes additional information regarding its business strategy, liquidity position and certain pro forma 2025 financial information, is available on its website.

About MindMaze Therapeutics
MindMaze Therapeutics is a Swiss-based, commercial-stage company that develops and commercializes first-of-its-kind digital treatments for neurological diseases and brain disorders. Built on an advanced brain technology platform integrating software, sensors, and telehealth, its solutions are deployed globally across clinics and home settings. MindMaze Therapeutics’ clinically validated neurotherapeutics have demonstrated significant medico-economic outcomes across conditions such as stroke, Parkinson’s disease, and at-risk aging. The Company continues to expand its R&D pipeline into adjacent neurological indications, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer’s disease.

MindMaze Therapeutics is listed on the SIX Swiss Exchange under the ticker MMTX.

For more information, visit www.mindmazetherapeutics.com.

CONTACT
MindMaze Therapeutics Holding SA
Jeremy Meinen
Chief Financial Officer
ir@mindmazetherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company’s ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Frauenfeld, 3 March 2026

Press release
Ad hoc announcement pursuant to Art. 53 KR
 

DocMorris AG announces changes to its Board of Directors

DocMorris AG is planning personnel changes to the Board of Directors in view of the upcoming Annual General Meeting. Prof. Stefan Feuerstein, Dr Christian Mielsch and Rongrong Hu will not be standing for re-election. The Board of Directors proposes the election of Thomas Bucher, Dr Thomas Reutter and Nicole Formica-Schiller at the Annual General Meeting.

After many years of successful service to DocMorris, three current members of the Board of Directors, Prof. Stefan Feuerstein, Dr Christian Mielsch and Rongrong Hu, have decided to step down at the end of the Annual General Meeting on 12 May 2026. Stefan Feuerstein has played a key role in shaping the strategic development of the company, first as its long-standing Chairman and most recently as Vice-Chairman. Christian Mielsch has provided important impetus in strategic matters with his financial expertise. After many years of commitment, both wish to make room for new personal priorities and will not stand for re-election. Rongrong Hu has effectively contributed her international tech expertise and played a key role in strengthening DocMorris’ positioning. Due to a new professional commitment, she does not wish to continue her mandate on the Board of Directors.

In order to specifically complement the expertise of the Board and support the next phase of the company’s development, the Board of Directors proposes the election of the following independent individuals to the General Meeting:

Thomas Bucher (1966) has many years of international experience in the financial sector. From 2021 to 2025, he served as CFO of Archroma Management GmbH in Basel. Previously, he held CFO positions at Alpiq Holding AG in Lausanne and Gategroup AG in Zurich. He is a member of the Board of Directors of Swiss Post AG in Berne and Primeo Holding AG in Münchenstein. He studied economics at the University of St. Gallen and completed the INSEAD International Executive Program in Fontainebleau and Singapore.

Dr Thomas U. Reutter (1967) is an attorney at law with extensive expertise in M&A, capital markets and corporate governance. He has been a senior partner and co-founder of the law firm Advestra AG in Zurich since 2021. Prior to that, he spent 15 years as a partner at Bär & Karrer AG in Zurich, where he also led the capital markets practice and served on the executive board. He studied economics and law at the University of St. Gallen and holds a doctorate in law.

Nicole Formica-Schiller (1977) is an expert in AI and digitalisation, with proven experience in driving digital transformation. She combines in-depth knowledge of European AI regulation (EU AI Act) with strategic consulting for the healthcare industry, supporting the modernisation and digitalisation of, among others, the German healthcare system. Since 2016, she has served as CEO of Pamanicor Health AG in Zug, a global consulting firm she founded. She has held and continues to hold various board and expert committee positions, with a particular focus on AI and digital health. She is a fully qualified lawyer with a degree from Ludwig-Maximilians-Universität Munich, complemented by an additional degree in economics.

With these candidates, DocMorris ensures that the Board of Directors continues to have a balanced mix of industry knowledge, digital expertise and corporate governance experience.

“We would like to express our sincere thanks to Stefan Feuerstein, Christian Mielsch and Rongrong Hu for their great commitment and valuable work for DocMorris. They have accompanied the company through crucial phases of transformation. At the same time, we are delighted to be able to propose three distinguished individuals for election in Thomas Bucher, Thomas Reutter and Nicole Formica-Schiller, who will ideally complement our Board of Directors with their specific experience,” says Walter Oberhänsli, Chairman of the Board of Directors.

The invitation to the Annual General Meeting, including detailed profiles of the new candidates, will be published on 17 April 2026.
 

Investors and analyst contact
Moritz Stahlhut, Investor Relations Manager
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,000 physicians. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving 11 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Guidance 2026 –– New Share Buyback Program

The Executive Board of Beiersdorf Aktiengesellschaft, Hamburg, today resolved – with the approval of the Supervisory Board – the business plan for the financial year 2026.

The slowing skin care market and the volatile economic environment have a negative impact on the short-term growth outlook for Beiersdorf’s Consumer business segment. Despite these challenges, Beiersdorf will continue to pursue important planned strategic investments in its brands to secure mid- and long-term value generation. Against this backdrop, the Executive Board expects the Consumer business segment’s sales for the 2026 financial year to be flat to slightly growing organically and the EBIT margin (excluding special factors) to be slightly below previous year’s level.

For the tesa business segment, sales are expected to be flat to slightly growing organically for the 2026 financial year and – also due to investments in strategic growth areas – the EBIT margin (excluding special factors) is expected to be slightly below previous year’s level. On this basis, the Executive Board expects the Group to achieve flat to slightly growing organic sales in the 2026 financial year and an operating EBIT margin (excluding special factors) slightly below previous year’s level.

In the previous year 2025, organic sales growth was 2.4% with an operating EBIT margin (excluding special factors) of 14.0% at the Group level. In line with market expectations, the Consumer business segment achieved an organic sales growth of 2.5% with an operating EBIT margin (excluding special factors) of 13.6% and the tesa business segment an organic sales growth of 1.8% with an operating EBIT margin (excluding special items) of 16.1%.

Furthermore, the Executive Board today resolved – with the approval of the Supervisory Board – to buy back shares in the Company in the amount of up to €750 million over the next two years. This follows the successful completion of the share buyback programs in 2024 and 2025.
 

The Company will announce further details on the new share buyback program in accordance with the statutory provisions before the start of the share buyback program. Treasury shares held by the Company will be cancelled to the extent necessary to carry out the share buyback program.

Contact:
Christopher Sheldon
Head of Investor Relations
Tel.: +49 (40) 4909 5000
E-Mail: Investor.Relations@Beiersdorf.com

Florian Dieckmann
Head of Corporate Communications
Tel.: +49 (40) 4909 2001
E-Mail: cc@beiersdorf.com

O3 Holding GmbH – Publication Q4 2025 Interim Report

BIOGGIO, SWITZERLAND, 28 February 2026 – O3 Holding GmbH (the Company), the holding company of KD Pharma Group, a leading CDMO in pharmaceutical and nutritional lipids, announces that the publication of its Q4 2025 Interim Report, due  under the bond terms for The Company’s FRN Senior Secured EUR 180,000,000 bond issue with ISIN NO0013360552 issued on 28 October 2024, has now been published on the Company’s website (www.kdpharmagroup.com/investor-relations).

For further information please contact:

investor.relations@kdpharmagroup.com

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – 

– Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – 

– Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization – 

NEW YORK, February 26, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate update.

“The phase 3 ENSURE-1 and ENSURE-2 trials of our lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS) continue to progress, with top-line data expected to be available by the end of 2026,” stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. “As we continue to advance our multiple sclerosis (MS) program with vidofludimus calcium, we were extremely pleased to have recently announced the successful completion of an oversubscribed private placement of up to $400 million in gross proceeds, with $200 million in upfront gross proceeds. This financing is truly a pivotal milestone for Immunic and positions us to confidently transition into a fully integrated commercial-stage company. The transaction was led by our existing investor BVF Partners L.P. with participation from a group of highly regarded new and other existing investors. This level of commitment reflects growing confidence in our program and reinforces our belief in vidofludimus calcium’s potential to address the underlying drivers of MS progression.”

“The proceeds from the initial closing are expected to fund our operations through the ENSURE top-line data and our planned RMS New Drug Application (NDA) submission in the United States in mid-2027, with a targeted potential regulatory approval date in 2028,” continued Dr. Vitt. “They also support preparations for the potential launch of vidofludimus calcium in RMS, including expansion of our medical and commercial infrastructure. Additionally, based on the totality of the phase 2 CALLIPER trial data in progressive MS, which showed not only substantial and medically relevant reductions for vidofludimus calcium in delaying 24-week confirmed disability progression but also statistically significant 24-week confirmed disability improvement, while confirming the drug’s favorable safety and tolerability profile already observed in previous clinical trials, we plan to initiate a confirmatory phase 3 program in primary progressive multiple sclerosis (PPMS) later this year as well.”

Jason Tardio, President and Chief Operating Officer of Immunic, added, “This is an exciting moment for Immunic and for individuals living with MS, as we believe that vidofludimus calcium could represent a potentially transformative approach to disease modification. Current oral therapies for RMS mainly control inflammation and relapses, often have complex safety and tolerability issues and do not adequately address the neurodegenerative processes driving disability progression and long-term disability. In contrast, vidofludimus calcium is uniquely designed to provide direct neuroprotective effects by enhancing neuronal survival and function through Nurr1 activation, while reducing new inflammatory damage via selective DHODH inhibition. This first-in-class mechanism has the potential to address the two key biological drivers of disability progression—relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA)—potentially offering advantages over currently available therapies that primarily focus on inflammatory relapses. As such, we believe vidofludimus calcium may achieve a best-in-class benefit-risk profile and, therefore, could represent a large commercial opportunity in the global MS market, which is projected to reach over $30 billion by the early 2030s.” 

Fourth Quarter 2025 and Subsequent Highlights 

• February 2026: Completed an oversubscribed private placement of up to $400 million in gross proceeds, led by existing investor BVF Partners L.P. with participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners, Vivo Capital, Woodline Partners LP, and other institutional investors. A total of $200 million in gross proceeds to Immunic was received upon closing on February 17, 2026.
  • Simona Skerjanec, former SVP, Global Head of Neuroscience and Rare Diseases at Roche, elevated to Interim Chairperson of the Board of Directors. Dr. Duane Nash, former Chairman, remains a member of the Board. Thor Nagel, Principal at BVF Partners L.P., appointed to the Board. Plans underway for further Board refreshment to support the company’s evolution into a commercial-stage organization.
  • Initiated search for a new Chief Executive Officer with deep commercial expertise in MS to lead Immunic into its next stage of growth and commercialization. Subsequently, Dr. Vitt will return to his roots and transition to a new senior executive role focused on scientific strategy and portfolio advancement, while remaining on the Board.
• February 2026: Presented additional data from the phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive MS at the ACTRIMS Forum 2026. The findings, presented in two poster presentations, provide additional evidence of vidofludimus calcium’s effects on key biological drivers of disease progression, including antiviral immune responses linked to Epstein-Barr virus (EBV) and magnetic resonance imaging (MRI) markers of both acute-focal and chronic-compartmentalized inflammation. The findings further reinforce Immunic’s belief that vidofludimus calcium has the potential to address underlying mechanisms of disease progression in MS patients.

Anticipated Clinical Milestones

• Vidofludimus calcium in MS:

• Top-line data from the twin phase 3 ENSURE-1 and ENSURE-2 trials in RMS is expected by the end of 2026. Subsequently, Immunic plans to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval date in 2028.
• Initiation of a phase 3 clinical program in PPMS is expected later this year and estimated to take approximately 3.5 to 4 years to complete.

• IMU-856: The company continues preparing for further clinical testing of IMU-856, contingent on financing, licensing or partnering.

Financial and Operating Results 

• Research and Development (R&D) Expenses were $82.0 million for the twelve months ended December 31, 2025, as compared to $80.0 million for the twelve months ended December 31, 2024. The $1.9 million increase reflects (i) a $3.9 million increase in external development costs related to the vidofludimus calcium program and (ii) a $1.8 million increase in personnel expenses for R&D. The increase was offset by (i) a $3.0 million decrease in external development costs related to IMU-856 and (ii) a $0.8 million decrease across numerous categories.
• General and Administrative (G&A) Expenses were $21.2 million for the twelve months ended December 31, 2025, as compared to $18.0 million for the same period ended December 31, 2024. The $3.2 million increase was due to (i) a $1.9 million increase related to personnel expenses, of which $0.3 million was related to non-cash stock compensation, (ii) a $0.8 million increase in legal and consultancy expenses and (iii) a $0.5 million increase related to costs across numerous categories. 
• Interest Income was $1.0 million for the twelve months ended December 31, 2025, as compared to $3.4 million for the twelve months ended December 31, 2024. The $2.4 million decrease was due to a lower average cash balance.
• In the twelve months ended December 31, 2024, there was a non-cash charge related to the change in value of the tranche rights associated with the January 2024 Financing from January 8, 2024 until March 4, 2024. These tranches were initially classified as a liability, but were reclassified to equity on March 4, 2024, when stockholders approved the increase in the company’s authorized shares from 130 million to 500 million shares of common stock and, therefore, the tranche 2 and tranche 3 rights needed to be revalued to fair value upon the reclassification to equity. There was no change in fair value of the tranche rights recognized in the twelve months ended December 31, 2025.
• Other Income (Expense) was $5.0 million for the twelve months ended December 31, 2025, as compared to ($1.0 million) for the same period ended December 31, 2024. The $6.1 million increase was primarily attributable to (i) $4.8 million of grant income from the German Federal Ministry of Finance, of which $1.0 million was recognized in the first quarter 2025 and $3.8 million was recognized in the fourth quarter 2025, (ii) a $1.7 million expense related to the portion of deal costs from the January 2024 Financing related to the tranche rights that were established at the time of the deal closing in 2024 and (iii) a $0.3 million increase across numerous categories. The increase was offset by a $0.7 million decrease in research and development tax incentives for clinical trials in Australia due to lower clinical trial spend in Australia.
• Net Loss for the twelve months ended December 31, 2025, was approximately $97.2 million, or $0.62 per basic and diluted share, based on 155,688,030 weighted average common shares outstanding, compared to a net loss of approximately $100.5 million, or $1.00 per basic and diluted share, based on 100,174,766 weighted average common shares outstanding for the same period ended December 31, 2024.
• Cash and Cash Equivalents as of December 31, 2025 were approximately $15.5 million. With these funds and the approximately $187.0 million net cash proceeds raised in the February 2026 private placement, Immunic expects to be able to fund its operations into late 2027. 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases such as celiac disease, inflammatory bowel disease, and Graft-versus-Host-Disease. IMU-381 comprises next-generation molecules in preclinical testing for neurologic, gastrointestinal and other autoimmune diseases leveraging the company’s Nurr1 platform. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for Immunic’s development programs to safely and effectively target diseases; preclinical and clinical data for Immunic’s development programs; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, and the ability to raise sufficient capital to continue as a going concern, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

Berlin, Germany, 26 February 2026. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today announced that it has entered a partnership with Molecular Partners AG to enable the development and future manufacturing of Molecular Partners’ radiolabeled therapeutics (Radio-DARPins) based on its proprietary Designed Ankyrin Repeat Protein (DARPin) technology platform.

Under the agreement, Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with Actinium-225 and Lutetium-177 payloads which show potential in the treatment of various cancers. The collaboration will leverage Eckert & Ziegler’s state-of-the-art laboratories, including the newly established development laboratory in Berlin. Thanks to its carefully selected and matched technical equipment, the facility offers ideal conditions for the advancement of radiopharmaceuticals based on alpha emitters.

DARPin molecules are a novel class of custom-built proteins. Their structure and favorable pharmacokinetic properties make them an attractive vector for the development of targeted radiopharmaceuticals, with the potential to address significant unmet medical needs.

“Supporting highly innovative companies such as Molecular Partners in developing their promising technology platforms is a key objective of our group,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “Bringing together our expertise in isotopes, radiochemistry and development infrastructure with our partners’ innovations will enable patients worldwide to benefit from new treatments in the future.”

The collaboration further strengthens Eckert & Ziegler’s position as a preferred partner for companies developing innovative radiopharmaceutical platforms and underscores its role in supporting the growing radiopharmaceutical ecosystem from early development through clinical supply to commercial phases.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

Molecular Partners
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35